Health Tech, Devices & Diagnostics, Startups, BioPharma, Artificial Intelligence

Voluntis gets FDA nod for its Oleena cancer management product

The company’s software acts as an aid for cancer patients by helping users self-manage their disease symptoms and allow for remote monitoring by clinicians through mobile and web technologies.

French digital health company Voluntis recently received clearance by the FDA for its cancer management platform.

Dubbed Oleena, the company’s software acts as an aid for cancer patients by helping users self-manage their disease symptoms and allow for remote monitoring by clinicians through mobile and web technologies.

“Beyond monitoring their symptoms, we believe that empowering patients via the digital delivery of real-time and personalized therapeutic interventions offers the opportunity for significant clinical and economic outcomes,” said Voluntis CEO Pierre Leurent in a statement.

Better managing symptoms, the theory goes, helps to improve overall health outcomes and decrease emergency hospitalizations and unplanned treatment interruptions.

The prescription-only digital therapeutic is intended to give patients contextually relevant and personalized recommendations on actions to help manage symptoms including guiding individuals in proper dosing and use of therapeutics. The company’s proprietary algorithms are customized according to a patient’s individual health situation and clinical care plan.

Oleena has been developed to work across a range of cancer types and anti-cancer treatments including chemotherapies, immunotherapies and targeted therapies. Among the symptoms managed by the tool are common issues associated with cancer like diarrhea, pain and nausea.

Sponsored Post

Physician Targeting Using Real-time Data: How PurpleLab’s Alerts Can Help

By leveraging real-time data that offers unprecedented insights into physician behavior and patient outcomes, companies can gain a competitive advantage with prescribers. PurpleLab®, a healthcare analytics platform with one of the largest medical and pharmaceutical claims databases in the United States, recently announced the launch of Alerts which translates complex information into actionable insights, empowering companies to identify the right physicians to target, determine the most effective marketing strategies and ultimately improve patient care.

Data from a patient’s use of the system is then fed back to their clinical team who can use the information to adjust their care plan and gain additional clinical insights into the person’s condition.

“Digital therapeutics like Oleena represent a critically important addition to the management of symptoms at oncology practices level. The plain language and the user-friendly interfaces simplify the patient self-management,” Dr. Arvind Dasari, an oncologist at University of Texas MD Anderson Cancer Center in a statement.

“The embedded clinical algorithms enable automated and proactive intervention that aid health care teams, both in terms of personalization and standardization.”

Voluntis has developed other disease management tools, although Oleena is the company’s first FDA-cleared product in the oncology space. The company’s other digital therapeutics include Insulia and Diabeo, which helps patients better control their diabetes symptoms and guides users in their insulin dosage.

Photo: Natali_Mis, Getty Images